Corporate Governance Overview

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

The Board of Directors of Nurix Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

	Audit Committee	Compensation Committee	Development Advisory Committee	Nominating and Corporate Governance Committee
Julia P. Gregory	Audit Committee			Nominating and Corporate Governance Committee
Lori A. Kunkel, M.D.		Compensation Committee	Development Advisory Committee
David Lacey, M.D.		Compensation Committee	Development Advisory Committee
Judith A. Reinsdorf, J.D.	Audit Committee			Nominating and Corporate Governance Committee
Edward C. Saltzman		Compensation Committee	Development Advisory Committee
Arthur Sands M.D., Ph.D.
Paul M. Silva	Audit Committee			Nominating and Corporate Governance Committee

= Chairperson = Member = Chairman of the Board

Investors

Corporate Profile

Corporate Governance Overview